Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1995 Sep;54(9):726–729. doi: 10.1136/ard.54.9.726

Lp(a) lipoprotein levels as a predictor of risk for thrombogenic events in patients with Behçet's disease.

A Orem 1, O Değer 1, O Memiş 1, S Bahadir 1, E Ovali 1, G Cimşit 1
PMCID: PMC1009987  PMID: 7495343

Abstract

OBJECTIVES--To investigate whether plasma levels of Lp(a) lipoprotein (Lp(a)) are predictors of defective fibrinolytic activity, leading to thrombosis, in patients with Behçet's disease. METHODS--Plasma Lp(a) was measured by enzyme linked immunosorbent assay, lipids and lipoproteins by enzymatic methods, and apolipoproteins A-I and B, fibrinogen (turbidimetric method), tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), and D-dimer levels by enzyme immunoassay. Their levels and interactions were evaluated in 33 patients with Behçet's disease (including five with thrombotic complications) and 30 healthy control subjects. RESULTS--Plasma Lp(a) concentration was significantly greater in the patients than in controls. Nine patients (27%) had levels > 0.30 microgram. There was no correlation between Lp(a) and other lipids and lipoproteins apart from apolipoprotein B. Lp(a) showed inverse correlation with t-PA (r = -0.34, p < 0.05) and D-dimer (r = 0.35, p < 0.05). Patients with thrombotic complications had significantly greater Lp(a) and PAI-1, and lower D-dimer concentrations than control subjects. CONCLUSIONS--Measurement of plasma Lp(a) levels in patients with Behçet's disease may provide useful information regarding the potential development of thrombotic events, because of its possible role in defective fibrinolysis.

Full text

PDF
726

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aitchison R., Chu P., Cater D. R., Harris R. J., Powell R. J. Defective fibrinolysis in Behçet's syndrome: significance and possible mechanisms. Ann Rheum Dis. 1989 Jul;48(7):590–593. doi: 10.1136/ard.48.7.590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Albers J. J., Cabana V. G., Warnick G. R., Hazzard W. R. Lp(a) lipoprotein: relationship to sinking pre-beta lipoprotein hyperlipoproteinemia, and apolipoprotein B. Metabolism. 1975 Sep;24(9):1047–1054. doi: 10.1016/0026-0495(75)90098-0. [DOI] [PubMed] [Google Scholar]
  3. Etingin O. R., Hajjar D. P., Hajjar K. A., Harpel P. C., Nachman R. L. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem. 1991 Feb 5;266(4):2459–2465. [PubMed] [Google Scholar]
  4. Glueck C. J., Glueck H. I., Tracy T., Speirs J., McCray C., Stroop D. Relationships between lipoprotein(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimer. Metabolism. 1993 Feb;42(2):236–246. doi: 10.1016/0026-0495(93)90042-m. [DOI] [PubMed] [Google Scholar]
  5. Gonzalez-Gronow M., Edelberg J. M., Pizzo S. V. Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein a compete for the same site. Biochemistry. 1989 Mar 21;28(6):2374–2377. doi: 10.1021/bi00432a005. [DOI] [PubMed] [Google Scholar]
  6. Hajjar K. A., Gavish D., Breslow J. L., Nachman R. L. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989 May 25;339(6222):303–305. doi: 10.1038/339303a0. [DOI] [PubMed] [Google Scholar]
  7. Halvorsen S., Skjønsberg O. H., Berg K., Ruyter R., Godal H. C. Does Lp(a) lipoprotein inhibit the fibrinolytic system? Thromb Res. 1992 Nov 1;68(3):223–232. doi: 10.1016/0049-3848(92)90080-t. [DOI] [PubMed] [Google Scholar]
  8. Hampton K. K., Chamberlain M. A., Menon D. K., Davies J. A. Coagulation and fibrinolytic activity in Behçet's disease. Thromb Haemost. 1991 Sep 2;66(3):292–294. [PubMed] [Google Scholar]
  9. Hamza M. Large artery involvement in Behçet's disease. J Rheumatol. 1987 Jun;14(3):554–559. [PubMed] [Google Scholar]
  10. Kluft C., Michiels J. J., Wijngaards G. Factual or artificial inhibition of fibrinolysis and the occurrence of venous thrombosis in 3 cases of Behçet's disease. Scand J Haematol. 1980 Nov;25(5):423–430. doi: 10.1111/j.1600-0609.1981.tb01424.x. [DOI] [PubMed] [Google Scholar]
  11. Maeda S., Abe A., Seishima M., Makino K., Noma A., Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis. 1989 Aug;78(2-3):145–150. doi: 10.1016/0021-9150(89)90218-9. [DOI] [PubMed] [Google Scholar]
  12. Miles L. A., Fless G. M., Levin E. G., Scanu A. M., Plow E. F. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 1989 May 25;339(6222):301–303. doi: 10.1038/339301a0. [DOI] [PubMed] [Google Scholar]
  13. Miles L. A., Plow E. F. Lp(a): an interloper into the fibrinolytic system? Thromb Haemost. 1990 Jun 28;63(3):331–335. [PubMed] [Google Scholar]
  14. Mishima H., Masuda K., Shimada S., Toki N., Tsushima H., Gocho M. Plasminogen activator activity levels in patients with Behçet's syndrome. Arch Ophthalmol. 1985 Jul;103(7):935–936. doi: 10.1001/archopht.1985.01050070061030. [DOI] [PubMed] [Google Scholar]
  15. Orem A., Değer O., Kulan K., Onder E., Kiran E., Uzunosmanoğlu D. Evaluation of lipoprotein (a) [Lp (a)] as a risk factor for coronary artery disease in the Turkish population. Clin Biochem. 1995 Apr;28(2):171–173. doi: 10.1016/0009-9120(94)00078-a. [DOI] [PubMed] [Google Scholar]
  16. Orem A., Değer O., Memiş O., Calişkan K., Cimşit G. High lipoprotein (a) levels as a thrombogenic risk factor in Behçet's disease. Ann Rheum Dis. 1994 May;53(5):351–352. doi: 10.1136/ard.53.5.351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Orem A., Değer O., Onder E., Karahan S. C., Efe H., Uzunosmanoğlu D. Distribution of serum lipoprotein (a) concentrations in a healthy Turkish population. Ann Clin Biochem. 1994 Jul;31(Pt 4):343–346. doi: 10.1177/000456329403100406. [DOI] [PubMed] [Google Scholar]
  18. Rantapä-Dahlqvist S., Wållberg-Jonsson S., Dahlén G. Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis. 1991 Jun;50(6):366–368. doi: 10.1136/ard.50.6.366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Samlaska C. P., James W. D. Superficial thrombophlebitis. II. Secondary hypercoagulable states. J Am Acad Dermatol. 1990 Jul;23(1):1–18. doi: 10.1016/0190-9622(90)70179-l. [DOI] [PubMed] [Google Scholar]
  20. Scanu A. M. Lipoprotein(a): its inheritance and molecular basis of its atherothrombotic role. Mol Cell Biochem. 1992 Aug 18;113(2):127–131. doi: 10.1007/BF00231532. [DOI] [PubMed] [Google Scholar]
  21. Schmitz-Huebner U., Knop J. Evidence for an endothelial cell dysfunction in association with Behçet's disease. Thromb Res. 1984 May 15;34(4):277–285. doi: 10.1016/0049-3848(84)90384-0. [DOI] [PubMed] [Google Scholar]
  22. Slunga L., Johnson O., Dahlén G. H., Eriksson S. Lipoprotein(a) and acute-phase proteins in acute myocardial infarction. Scand J Clin Lab Invest. 1992 Apr;52(2):95–101. doi: 10.3109/00365519209088771. [DOI] [PubMed] [Google Scholar]
  23. Smith E. B., Crosbie L. Does lipoprotein(a) (Lp(a)) complete with plasminogen in human atherosclerotic lesions and thrombi? Atherosclerosis. 1991 Aug;89(2-3):127–136. doi: 10.1016/0021-9150(91)90052-5. [DOI] [PubMed] [Google Scholar]
  24. Smith E. B. Fibrinogen and atherosclerosis. Wien Klin Wochenschr. 1993;105(15):417–424. [PubMed] [Google Scholar]
  25. Thiery J., Armstrong V. W., Schleef J., Creutzfeldt C., Creutzfeldt W., Seidel D. Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor. Klin Wochenschr. 1988 May 16;66(10):462–463. doi: 10.1007/BF01745519. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES